Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





SULPROFOS								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 35400-43-2; **Chemical Formula:** C12H19O2PS3
OSHA’s Z tables formerly had no limit for sulprofos. The ACGIH has an exposure limit of 1 mg/m3 as an 8-hour TWA. The proposed PEL was 1 mg/m3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurred with this limit, and OSHA establishes this limit in the final rule. Sulprofos, also known as the insecticide BolstarR, is a tan liquid.
Kimmerle (1982b, as cited in ACGIH 1986/Ex. 1-3, p. 547) conducted an extensive animal study on the effects of sulprofos. He reported that the acute toxicity of sulprofos is species-dependent; rats have an oral LD(50) of 100 to 300 mg/kg and mice have an oral LD(50) of 1600 to 1800 mg/kg. The reported dermal LD(50)s are greater than 1000 ml/kg in rats and 800 to 1000 mg/kg in rabbits. In rabbits, sulprofos did not irritate the skin or eyes, and it had no dermal-sensitization effects in guinea pigs. Inhalation studies showed no fatalities in rats exposed to aerosol concentrations of up to 4130 mg/m3 of sulprofos over a period of four hours. In a three-week inhalation study in which rats were exposed to aerosol concentrations of 6, 14, or 74 mg/m3, the two highest concentrations produced cholinergic symptoms; no observable effects were seen at the lowest concentration. Two-year feeding studies by Kimmerle (1982b, as cited in ACGIH 1986/Ex. 1-3, p. 547) in dogs, rats, and mice showed that sulprofos concentrations of 150 ppm, 250 ppm, or 400 ppm were tolerated by all species, with no sulprofos-related tissue changes, signs of toxicity, or oncogenic effects. The overall NOELs were 10 ppm in dogs, 6 ppm in rats, and 2.5 ppm in mice. Kimmerle’s ingestion studies in rats and rabbits dosed at levels of 3, 10, or 30 mg/kg/day of sulprofos showed no embryotoxic or teratogenic effects in these animals, and a three-generation diet study in rats also produced no adverse reproductive effects. Mutagenic studies reported by the same author in mice were negative. Separate subacute inhalation studies also showed no effects on blood cholinesterase levels in rats exposed to 6 mg/m3 (Zielhuis and van der Kreek 1979/Ex. 1-613). There are no reported cases of poisoning in humans (ACGIH 1986/Ex. 1-3, p. 547). NIOSH was the only commenter on sulprofos.
In the final rule, OSHA is establishing an 8-hour TWA limit of 1 mg/m3 for sulprofos. This agency concludes that this limit will protect workers from the significant risk of cholinesterase inhibition, the most sensitive indicator of exposure to this previously unregulated substance. The Agency has determined that this limit will substantially reduce this significant risk, and that cholinesterase inhibition constitutes a material impairment of health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue